Market Cap : 2.16 B | Enterprise Value : 2.18 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PTC Therapeutics's Operating Income for the three months ended in Mar. 2022 was $-98.2 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 was $-375.1 Mil.
Operating Margin % is calculated as Operating Income divided by its Revenue. PTC Therapeutics's Operating Income for the three months ended in Mar. 2022 was $-98.2 Mil. PTC Therapeutics's Revenue for the three months ended in Mar. 2022 was $148.7 Mil. Therefore, PTC Therapeutics's Operating Margin % for the quarter that ended in Mar. 2022 was -66.04%.
Good Sign:
PTC Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.
PTC Therapeutics's 5-Year average Growth Rate for Operating Margin % was 0.40% per year.
Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PTC Therapeutics's annualized ROC % for the quarter that ended in Mar. 2022 was -29.21%. PTC Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 was -296.78%.
The historical data trend for PTC Therapeutics's Operating Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.
Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-375.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
PTC Therapeutics's annualized ROC % for the quarter that ended in Mar. 2022 is calculated as:
ROC % (Q: Mar. 2022 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Dec. 2021 ) | + | Invested Capital (Q: Mar. 2022 )) | / count ) |
= | -392.888 * ( 1 - -3.97% ) | / | ( (1390.417 | + | 1406.111) | / 2 ) |
= | -408.4856536 | / | 1398.264 | |||
= | -29.21 % |
where
Invested Capital | (Q: Dec. 2021 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1938.056 | - | 102.619 | - | ( 773.376 | - | max(0, 509.348 | - | 954.368 | + | 773.376 | )) |
= | 1390.417 |
Invested Capital | (Q: Mar. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 1799.591 | - | 96.247 | - | ( 587.793 | - | max(0, 476.776 | - | 774.009 | + | 587.793 | )) |
= | 1406.111 |
Note: The Operating Income data used here is four times the quarterly (Mar. 2022) data.
2. Joel Greenblatt's definition of Return on Capital:
PTC Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2022 is calculated as:
ROC (Joel Greenblatt) % | (Q: Mar. 2022 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Dec. 2021 | Q: Mar. 2022 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -393.508 | / | ( ( (130.006 + max(-168.543, 0)) | + | (135.181 + max(-131.698, 0)) ) | / | 2 ) |
= | -393.508 | / | ( ( 130.006 | + | 135.181 ) | / | 2 ) |
= | -393.508 | / | 132.5935 | ||||
= | -296.78 % |
where Working Capital is:
Working Capital | (Q: Dec. 2021 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (110.455 | + | 15.856 | + | 54.681) | - | (102.619 | + | 0 | + | 246.916) |
= | -168.543 |
Working Capital | (Q: Mar. 2022 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (141.288 | + | 15.281 | + | 29.647) | - | (96.247 | + | 0 | + | 221.667) |
= | -131.698 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Mar. 2022) EBIT data.
3. Operating Income is also linked to Operating Margin %:
PTC Therapeutics's Operating Margin % for the quarter that ended in Mar. 2022 is calculated as:
Operating Margin % | = | Operating Income (Q: Mar. 2022 ) | / | Revenue (Q: Mar. 2022 ) |
= | -98.222 | / | 148.735 | |
= | -66.04 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.
Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of PTC Therapeutics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Zacks 2021-10-21
By Seekingalpha 2021-07-29
By Seekingalpha 2021-02-26
By Zacks 2021-05-04
By Seekingalpha 2021-01-23
By Zacks 2022-03-14
By Zacks 2022-04-04
By Zacks 2021-05-27
By Seekingalpha 2022-01-12
By Seekingalpha 2022-02-23
By Seekingalpha 2021-01-20